Non-Small-Cell Lung Cancer (NSCLC): The Changes of Molecular Immunotherapy and Targeted Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (25 December 2022) | Viewed by 29577
Special Issue Editors
Interests: lung cancer; pleural cancer
Special Issues, Collections and Topics in MDPI journals
Interests: tumors in the elderly; chronic fatigue syndrome; long-term cancer survivorship; ozone therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Worldwide, lung cancer is the most common cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) is the most common variety accounting for 84% of the cases. Molecular targeted therapies and immunotherapies for NSCLC have improved outcomes markedly over the past two decades. However, the vast majority of advanced NSCLCs become resistant to current treatments and eventually progress.
In this perspective, This Special Issue of IJMS seeks to compile a series of original research articles and timely, comprehensive reviews encompassing all aspects of NSCLC. Investigations into the myriad changes within the tumor microenvironment, including angiogenesis, invasion, epithelial–mesenchymal transition, cancer stem cells, deciphering molecular changes, and identifying biomarkers and predictors of prognosis and behavior, as well as advances in therapeutic options and resistance mechanisms, are topics of special interest. Contributions on other significant topics that further enhance our understanding of Molecular Immunotherapy and Targeted Therapy of NSCLC are also welcome.
Prof. Dr. Alessandra Bearz
Prof. Dr. Umberto Tirelli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NSCLC
- lung disease
- target therapy
- immunotherapy
- cerebral metastasis